<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Burmester, Gerd-Rüdiger</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Short- and Long-Term Efficacy of Tofacitinib in the Treatment of Patients with RA and an Inadequate Response to TNF Inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-18</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment with the oral Janus kinase (JAK) inhibitor tofacitinib was associated with an improvement in the signs and symptoms of rheumatoid arthritis (RA), physical function, and patient reported outcomes in RA patients with an inadequate response to tumor necrosis factor inhibitors (TNFi). The improved response was maintained over 24 months.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>